Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BERUBICIN
2024-516773-69-00Phase 2Completed
- Sponsor
- Pomeranian Medical University in Szczecin
- Start
- Nov 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of berubicin in primary central nervous system lymphoma (PCNSL) and non-Hodgkin lymphoma (NHL), sponsored by Pomeranian Medical University in Szczecin. Primary endpoint: Safety and tolerability of Berubicin in combination with other cytostatic agents. Started Nov 2024; status: completed.
02
Drugs
berubicin
03
Conditions
primary central nervous system lymphoma (PCNSL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2024-516773-69-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516773-69-00.